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PTelomere Length of Circulating Leukocytes Is
Decreased in Patients With Chronic Heart Failure
Pim van der Harst, MD, PHD,*† Gerrit van der Steege, PHD,‡ Rudolf A. de Boer, MD, PHD,*
Adriaan A. Voors, MD, PHD,* Alistair S. Hall, MD, PHD,§ Marcel J. Mulder,‡
Wiek H. van Gilst, PHD,† Dirk J. van Veldhuisen, MD, PHD, FACC,*
on behalf of the MERIT-HF Study Group
Groningen, the Netherlands; and Leeds, United Kingdom
Objectives This study sought to test the hypothesis that patients with chronic heart failure (CHF) have shorter telomeres
compared with age-balanced and gender-balanced healthy individuals.
Background Telomere length is considered to be a marker of biological aging. Chronic heart failure might be viewed as a
condition associated with accelerated biological aging.
Methods The telomere length ratio of leukocytes was determined prospectively by a quantitative polymerase chain
reaction–based method in a case-control setting involving 803 participants: 183 healthy individuals and 620
CHF patients, ages 40 to 80 years, New York Heart Association functional class II to IV, and left ventricular ejec-
tion fraction of 0.40 or less.
Results The median telomere length ratio was 0.64 (interquartile range [IQR] 0.47 to 0.88) in CHF patients compared
with 1.05 (IQR 0.86 to 1.29) in control patients (p  0.001). The telomere length ratio in CHF patients related to
severity of disease (median value [IQR] of patients with New York Heart Association class II, III, or IV function
was 0.67 [0.48 to 0.92], 0.63 [0.46 to 0.86], and 0.55 [0.46 to 0.75], respectively; p for trend 0.05). In addi-
tion, telomeres were shorter in patients with an ischemic compared with a nonischemic etiology of CHF. Patients
with none, 1 (coronary, cerebral, or peripheral vascular disease), 2 (any combination of the previous), or 3 ath-
erosclerotic manifestations had a median (IQR) telomere length of 0.72 (0.51 to 1.01), 0.65 (0.48 to 0.87),
0.48 (0.39 to 0.72), and 0.43 (0.27 to 0.67), respectively (p for trend 0.001).
Conclusions Telomere length is shorter in patients with CHF compared with age-balanced and gender-balanced control pa-
tients, and related to the severity of disease. In addition, telomere length was incrementally shorter according to
the presence and extent of atherosclerotic disease manifestations. (J Am Coll Cardiol 2007;49:1459–64)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.027s
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nelomeres are the distal ends of chromosomes that in
umans consist of long arrays of (TTAGGG)n tandem
epeat motifs that act as a cap for the ends of chromosomes.
his provides protection from structural degradation, inap-
ropriate recombination, and end-to-end fusion of chromo-
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ccepted November 27, 2006.omes (1,2). Initial telomere length is known to be deter-
ined by genetic and environmental factors (3–7).
owever, at each cell division deoxyribonucleic acid (DNA)
olymerases fail to completely replicate telomeres, thereby
esulting in a process of cumulative erosion (8). Consequently,
he structural integrity of the chromosomes becomes increas-
ngly vulnerable with the sequential cell divisions associated
ith the repair processes that accompany physiological and
athological aging. When telomeres reach a critical length,
ells enter replicative senescence, becoming apoptotic or oth-
rwise genomically unstable (1,2). Telomere length thus plays
critical role in maintaining the integrity of DNA and
onsequently the health of cells, and can be considered to be a
arker of overall biological age as compared with pure chro-
ological age based entirely on years of life (9).
Oxidative stress, inflammation, and increased leukocyteurnover are major environmental factors associated with
bi
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Telomere Length and Chronic Heart Failure April 3, 2007:1459–64accelerated telomere shortening
and biological aging (5–7), and
are also implicated in the causa-
tion of atherosclerosis. Perhaps
predictably, 2 small studies have
reported that telomeres were also
shorter in patients with athero-
sclerosis (10,11), and also those
with premature myocardial in-
farction, compared with age-
alanced and gender-balanced control subjects (12).
Because chronic heart failure (CHF) is associated with
ncreased systemic oxidative stress (13,14) and inflammation
15,16), we hypothesized that patients with CHF also
ould have decreased telomere length as measured for
hromosomes present within circulating leukocytes. We
tudied telomere length in 620 CHF patients and compared
ur findings with those from a group of 183 age-balanced
nd gender-balanced healthy control patients. We aimed to
nvestigate associations both between and within groups to
ssess impact of severity of CHF and also the presence of an
therosclerotic etiology.
ethods
atients and control patients. The study was conducted in
03 participants, of whom 620 were CHF patients who
articipated in the MERIT-HF (Metoprolol CR/XL Ran-
omized Intervention Trial in Congestive Heart Failure)
tudy (17) who had been recruited in either the Netherlands
r the United Kingdom and for whom DNA was collected
18,19). Details of the study design, inclusion and exclusion
riteria, and the present subpopulation have been published
reviously (17–19). In brief, all Dutch and United Kingdom
tudy participants were selected. They were ages 40 to 80
ears and had had symptomatic heart failure (New York
eart Association functional class II to IV) for 3 months or
ore. They were receiving optimum standard therapy at
nrollment and had a left-ventricular ejection fraction of
.40 or lower measured within 3 months before enrollment.
atient characteristics and events were recorded within the
ramework of the MERIT-HF. For the analysis in this
ubstudy, we used the MERIT-HF primary end point of
ll-cause mortality in combination with all-cause admission
o hospital (time to first event).
Control subjects were a priori selected from the genetic
atabase (n  777) of the department of Medical Biomics
f the University Medical Center Groningen, University of
roningen. This database consisted of healthy, non–blood-
elated relatives of patients with Crohn’s disease; ages
anged from 9 to 92 years, and 45% were of male gender.
alancing for age and gender was performed a priori
tratified for gender, and CHF patients were ranked for
ge. For the average age of 3 age-ranked CHF patients,
e aimed to select 1 control subject. We were able to
Abbreviations
and Acronyms
CHF  chronic heart failure
DNA  deoxyribonucleic
acid
IQR  interquartile range
PCR  polymerase chain
reactiondequately balance 183 control subjects. We only deter- rined telomere length in cases and the 183 selected
ontrols. All DNA samples, MERIT-HF samples, and
ontrol samples had been stored at 80°C at the depart-
ent of Medical Biomics. Determination of telomere
ength was performed prospectively.
We obtained ethical approval from the local regional
thics committees to perform this genetic substudy in the
utch and United Kingdom participants. This study con-
orms to the principles outlined in the Declaration of
elsinki.
elomere length assay. The DNA was collected at ap-
roximately 90 days after randomization and extracted
ccording to standard procedures (18,19). Mean telomere
ength was measured from DNA by a quantitative polymer-
se chain reaction (PCR)-based assay (20) based on the
84-well ABI7900HT TaqMan platform (Applied Biosys-
ems, Nieuwekerk aan de IJssel, the Netherlands). We
etermined the relative ratio of telomere repeat copy num-
er (T) to single-copy gene copy number (36B4 gene,
ncoding ribosomal phosphoprotein PO, located on chro-
osome 12; S) with all samples being compared with the
ame reference DNA sample. The T/S ratios have been
onfirmed previously to be highly consistent with the
lassical Southern blot on terminal restriction fragments
5,21). All DNA samples were assayed in duplicate on
eparate plates, but in the same well positions. The mean 
D coefficients of variation were 1.3% 1.2% for the T and
.6%  0.6% for S assay, respectively. Determination of T
nd S quantities was performed using standardized thresh-
lds and without knowledge of clinical data.
tatistical analysis. Because observed telomere lengths had
skewed distribution, the statistical analyses were per-
ormed on natural log-transformed data. Standard linear
egression techniques were used to associate telomere length
ith individual factors and to adjust for age (in years) and
ender (male or female).
One-way analysis of variance with the Scheffe post hoc
est was used for multiple comparisons. For event-free
urvival analysis, we used the log-rank test to compare
atients with a telomere length above or below the median
alue. In addition, we used Cox proportional hazards
egression analyses to assess telomere length as a continuous
ariable and to also to adjust for treatment allocation, age,
nd gender. A 2-sided p value 0.05 was interpreted as
ndicating a statistical significant difference. All analyses were
erformed using SPSS version 12.0 software (SPSS Inc.,
hicago, Illinois).
esults
aseline characteristics of the 620 CHF patients are pre-
ented in Table 1. The CHF patients (n  620) were
dequately balanced with the healthy control patients (n 
83) with respect to mean age (66.2  8.9 years vs. 66.2 
.7 years, respectively) and gender (79.3% vs. 79.3% male,
espectively). According to the case record forms, 183 (30%)
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April 3, 2007:1459–64 Telomere Length and Chronic Heart Failuref the 620 CHF patients had CHF of nonischemic etiology.
f these 183 patients, 40 patients did in fact have other
therosclerotic disease manifestations (peripheral or cere-
rovascular) or angina, leaving only 143 patients without
ny suggestion, signs, or symptoms of clinical manifesta-
ions of atherosclerosis.
In CHF patients, the telomere length ratio decreased
teadily with age at a mean yearly rate of 0.0079  0.0022
r0.143, p 0.001), which was identical in the control
ubjects (mean rate of 0.0077  0.0026; r  0.220, p 
.003 and p for interaction  0.98). Addition of squared
nd cubed age terms to the model had no significant effect
n telomere ratio for CHF patients (p 0.18 and p 0.28,
espectively) or for control subjects (p  0.75 and p  0.81,
espectively). This suggests a log-linear relationship be-
ween telomere length and age.
Samples of CHF patients were collected at a mean of 90
ays after randomization to placebo versus metoprolol.
owever, 90 days of metoprolol treatment did not affect
elomere length (placebo 0.63 [IQR 0.46 to 0.86] versus
etoprolol 0.65 [IQR 0.48 to 0.91], p  0.34).
We observed a highly significant difference in mean
elomere length ratio between CHF patients and control
Baseline Characteristics
Table 1 Baseline Characteristics
Characteristic
Total CHF
(n  620)
Nonisc
(n
Male 493 (80) 12
Age (yrs) 66 8.7 65
Caucasian race 604 (97) 18
Current daily smoker 90 (15) 3
Heart failure
Ischemic 437 (70)
Nonischemic 183 (30) 18
NYHA functional class
II 276 (45) 8
III 323 (52) 9
IV 21 (3)
Previous myocardial infarction 319 (52)
Angina 261 (42) 2
Stroke 38 (6)
Claudication 68 (11) 1
Hypertension 206 (33) 5
Diabetes mellitus 97 (16) 2
Ejection fraction 0.27 0.07 0.27
Heart rate (beats/min) 83 10 85
Blood pressure (mm Hg)
Systolic 132 19 132
Diastolic 78 9 79
Medication
Beta-blocker 315 (51) 9
ACE inhibitor 545 (88) 16
ARB 61 (10) 1
Diuretics 574 (93) 17
Data are number (%) or mean  SD.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptorubjects (median 0.64 [IQR 0.47 to 0.88] vs. 1.05 [IQR w.86 to 1.29], respectively; p  0.001) (Fig. 1). In addition,
he severity of the disease as indicated by New York Heart
ssociation functional class was associated with decreased
elomere length (Fig. 2A) and remained significant after
djustment for age and gender. The comparison between
ealthy control patients and nonischemic CHF patients
alidated the concept that CHF telomere length ratio was
ndeed shorter compared with healthy control patients (p 
.001) (Fig. 2B). Furthermore, ischemic etiology of CHF
as associated with shorter telomere length compared with
onischemic disease (Fig. 2B), also after adjustment for age
nd gender. Aside from coronary atherosclerosis, previous
troke and peripheral vascular disease were also negatively
orrelated with telomere length within the CHF population
Table 2). The regression coefficients of these variables
emained statistically significant after adjustment for chro-
ological age and gender (Table 2). In stepwise linear
egression with forced entry of age and gender, only
oronary artery disease (p  0.011), stroke (p  0.013), and
eripheral vascular disease (p  0.002) remained indepen-
ently associated with telomere length. Because coronary
isease, stroke, and peripheral vascular disease were inde-
endent predictors of shorter telomere length, we examined
CHF
)
Ischemic CHF
(n  437)
p Value
(Nonischemic vs. Ischemic)
366 (84) 0.001
67 8 0.013
424 (97) 0.339
60 (14) 0.390
437 (100)
) 0 (0)
0.111
190 (44)
228 (52)
19 (4)
319 (73) 0.001
240 (55) 0.001
29 (7) 0.416
55 (13) 0.046
151 (35) 0.278
74 (17) 0.172
8 0.27 0.07 0.694
82 10 0.002
132 19 0.788
78 9 0.080
219 (50) 0.594
384 (88) 0.970
43 (10) 0.999
401 (92) 0.229
r; CHF  chronic heart failure; NYHA  New York Heart Association.hemic
 183
7 (69)
 9.8
0 (98)
0 (16)
0 (0)
3 (100
6 (47)
5 (52)
2 (1)
0 (0)
1 (12)
9 (5)
3 (7)
5 (30)
3 (13)
 0.0
 11
 18
 9
6 (53)
1 (88)
8 (10)
3 (95)hether the coexistence of these atherosclerotic disease
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Telomere Length and Chronic Heart Failure April 3, 2007:1459–64ocations was incrementally associated with reduced telo-
ere length. Indeed, with an increasing number of athero-
clerotic manifestations present, telomere length was signif-
cantly and gradually shorter (Fig. 3). This remained
tatistically significant after adjustment for age and gender.
n contrast to telomere length, there was no association
etween chronological age and previous myocardial infarc-
ion (correlation coefficient 0.012), stroke (correlation coef-
cient 0.064), and peripheral vascular disease (correlation
oefficient 0.053) in our CHF population.
Telomere length was not related to the primary end point
f the MERIT-HF study (all-cause mortality or all-cause
ospitalization, time to first event) during 339  99 days of
ollow up (median 339). However, the primary end point of
he MERIT-HF study was mainly driven by all-cause
ospitalization, accounting for 92% of the events. The
bjective component of the primary end point, all-cause
ortality, was only reached in 13 patients, representing only
% of the primary end point. In addition, chronological age
lso did not predict event-free survival.
iscussion
he principal findings of the present study are that telomere
ength, as determined in peripheral leukocytes, is highly
ignificantly shorter in patients with CHF and also relates to
Figure 1 Telomere Length in
Control Patients and CHF Patients
Telomere length, expressed as the natural log (Ln) of the telomere to single
reference gene (T/S) ratio, is plotted as a function of age. The median telo-
mere length was 0.64 (interquartile range [IQR] 0.47 to 0.88) in chronic heart
failure (CHF) patients compared with 1.05 (IQR 0.86 to 1.29) in control pa-
tients (p  0.001). Yearly decline of telomere length ratio was 0.0079 
0.0022 in CHF patients and 0.0077  0.0026 in control patients (p  NS).
Linear regression line and mean 95% confidence interval lines are drawn for
CHF patients and control patients. Solid squares  controls; open circles 
CHF.he severity of the disease. Excluding ischemic CHF pa-ients did not change these findings. In addition, we
bserved telomere length to be shorter in CHF patients
ith ischemic compared with nonischemic etiology. Finally,
n patients with CHF, the concomitant presence and extent
f atherosclerotic disease manifestations was found to asso-
iate with even greater shortening of telomeres.
The exact mechanism explaining the relationship be-
ween shorter telomere length and CHF or atherosclerosis
annot be deduced from the current study. The main
uestion remains—whether shortening of the telomere is
ause or consequence in CHF and atherosclerosis, or
hether it is simply an epiphenomenon. In mice in which
elomerase was genetically knocked out, telomere shorten-
ng in subsequent generations was associated with the
evelopment of overt CHF (22). Although there is convinc-
ng evidence in humans for a role of telomere length in
yskeratosis congenita, a progressive bone marrow failure
Figure 2 Relationship Between Severity
and Etiology of CHF With Telomere Length
Median and interquartile range (box) of telomere length (A) of CHF patients
according to the severity of the disease measured by New York Heart Associa-
tion functional classification; telomere length is incrementally shortened with
increased New York Heart Association functional class (p  0.05 for trend).
(B) Patients with CHF have decreased telomere length compared with healthy
control patients (p  0.001). The CHF patients with concomitant coronary
artery disease (CAD) have further decreased telomere length (p  0.05).
Abbreviations as in Figure 1.
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April 3, 2007:1459–64 Telomere Length and Chronic Heart Failureyndrome (23,24), evidence in humans for a causal role of
elomeres in the pathophysiology of CHF and atheroscle-
osis remains to be established. Indeed, both CHF and
therosclerosis are related to increased oxidative stress and
nflammation (13–16,25). Oxidative stress and inflamma-
ion are important mediators of telomere attrition (5–7) and
ould explain the observed association.
We observed a linear yearly loss of telomere length ratio
f 0.008, which corresponds to approximately 23 to 26 base
airs of telomere sequence lost per year (5,21), and is in
ood accordance with attrition rates reported by others
sing alternative assays (3,11,12,26,27). However, when a
ecreased telomere length is largely acquired, one might
xpect an increased yearly telomere attrition rate to be
ssociated with CHF or atherosclerosis compared with
ontrol patients. However, we did not observe this. This is
n good agreement with a previous study, involving patients
ith premature (50 years) myocardial infarction (12), and
ight suggest an important heritable (3,4) component of
elomere length. Indeed, it might explain, at least in part,
he strong familial basis of CHF and atherosclerosis (28).
onversely and to an equal degree, the comparable yearly
ttrition rates between CHF patients and control patients
ould suggest that shorter telomeres have been acquired
arlier in life, or possibly even during intrauterine life, and
ender a phenotype more susceptible to CHF.
Independent of the reasons for the association between
elomere length and disease, the important question remains
hether variables other than the classic risk factors may
istinguish biological from chronological age and predict
he occurrence of cardiovascular events and death. A telo-
ere length measurement fulfils a number of criteria for a
obust biomarker of human aging. It changes progressively
ith chronological age, it varies considerably among indi-
iduals, and it is connected to the basic biology of aging
elationships of Age and Telomerength With Clinical Baseline Characteristicsithin Chronic He rt F ilur Popul tion (n  620)
Table 2
Relationships of Age and Telomere
Length With Clinical Baseline Characteristics
Within Chronic Heart Failure Population (n  620)
Variable
Telomere
(Std )* p Value
Telomere Corrected†
(Std ) p Value
Gender 0.058 0.152 0.061 0.126
Age 0.143 0.001 0.144 0.001
Hypertension 0.052 0.193 0.049 0.100
Diabetes mellitus 0.021 0.599 0.019 0.635
Current daily smoker 0.001 0.988 0.039 0.340
NYHA functional class 0.087 0.031 0.087 0.031
Ischemic etiology CHF 0.105 0.009 0.084 0.039
Previous myocardial 0.082 0.041 0.071 0.081
Infarction
Angina 0.119 0.003 0.103 0.010
Stroke 0.104 0.009 0.099 0.013
Claudication 0.141 0.001 0.130 0.001
Standardized  (Std ) reflects the change in the dependent variable for 1-SD change in the
ndependent variable. A larger Std  reflects greater strength of the associations. †Adjusted for age
nd gender.
Abbreviations as in Table 1.oth as a trigger of cellular senescence and as an indicator ofhe balance between oxidative stress and antioxidative de-
ense (29). Currently only 1 retrospective study has sug-
ested that short telomere length is an independent predic-
or of cardiovascular death in 143 subjects ages 60 years or
lder. However, the survival curves did not seem to divert
efore the first year of follow-up, and the survival advantage
f having longer telomeres was no longer significant in
ubjects more than 74 years old (30). In the current study,
either telomere length nor chronological age could predict
hort-term event-free survival during 339 days of follow-up.
owever, we have to consider that the primary end point
onsisted of both death and hospitalization for any cause.
nly 13 patients (8% of all events) reached the most
bjective component of the combined end point, namely
ll-cause mortality. This might have greatly limited our
esults, and therefore we are cautious about drawing any
onclusions. In other words, our study does not refute the
ypothesis that telomere length shows important prognostic
alue in CHF patients. Clearly, telomere length measure-
ents cannot be proposed as routine clinical assessment as
f this moment.
The present study has some other limitations that merit
onsideration. Telomere length per se is not the only critical
spect of telomere maintenance (1). For example, protection
f telomere ends is equally important and involves function-
ng of telomere associated proteins, such as TRF2 (31). We
lso did not determine telomerase activity. However, it has
een shown recently that not telomerase levels but short
elomeres themselves are the primary determinants of caus-
ng phenotypes (32). Unfortunately, within the MERIT
ramework no inflammatory markers are available. There-
ore, the potential relationship between telomere length and
nflammatory markers could not be assessed. During the
Figure 3 Number of Atherosclerotic Disease
Manifestations and Telomere Length in CHF Patients
Median and interquartile range (box) of telomere length of CHF patients is
gradually decreased according to the number of atherosclerotic disease mani-
festations: none, 1 (coronary, cerebrovascular, peripheral), 2 (any combination
of the previous), or 3. Abbreviations as in Figure 1.
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Telomere Length and Chronic Heart Failure April 3, 2007:1459–64urrent study, aldosterone blockade in CHF was not com-
on practice (33,34), which might have affected oxidative
tress and therefore telomere length. Finally, we reported
elomere length as T/S ratio, as determined by a real-time
CR-based method, instead of an “absolute” measure of
elomere length such as the (less sensitive) classic Southern
lot method on terminal restriction fragments. However,
se of real-time PCR-based T/S ratio to quantify telomere
ength has been confirmed previously to be highly consistent
ith the Southern blot (5,21). Compared with Southern
lot measurements, the real-time PCR approach is more
ensitive, more convenient for large-scale studies such as the
resent one, allows high throughput, requires considerably
ess DNA, and is less labor intensive (20). In addition, the
/S ratio of our control group was 1.1, the same as that of
he control group reported by Broberg et al. (35). Their 93
ontrol subjects, with a median age of 68 years and 19%
omen (current study, mean age 66 years and 21% women),
ere comparable with ours.
In conclusion, we found that patients with CHF are
haracterized by significantly shorter telomeres, and the
resence and extent of atherosclerotic disease was accom-
anied with even shorter telomeres in these patients. Future
esearch should be directed at elucidating the nature of the
trong association between telomere length and CHF or
therosclerosis in humans.
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